These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32361977)

  • 1. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
    Muehler A; Kohlhof H; Groeppel M; Vitt D
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):557-573. PubMed ID: 32361977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
    Muehler A; Peelen E; Kohlhof H; Gröppel M; Vitt D
    Mult Scler Relat Disord; 2020 Aug; 43():102129. PubMed ID: 32428844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
    Herrlinger KR; Diculescu M; Fellermann K; Hartmann H; Howaldt S; Nikolov R; Petrov A; Reindl W; Otte JM; Stoynov S; Strauch U; Sturm A; Voiosu R; Ammendola A; Dietrich B; Hentsch B; Stange EF
    J Crohns Colitis; 2013 Sep; 7(8):636-43. PubMed ID: 23078909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.
    Zhu G; Wang L; Zhong S; Han S; Peng H; Tong M; He X
    Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):207-217. PubMed ID: 38381348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.
    Muehler A; Kohlhof H; Groeppel M; Vitt D
    Drugs R D; 2019 Dec; 19(4):351-366. PubMed ID: 31621054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers.
    Badman MK; Chen J; Desai S; Vaidya S; Neelakantham S; Zhang J; Gan L; Danis K; Laffitte B; Klickstein LB
    Clin Pharmacol Drug Dev; 2020 Apr; 9(3):395-410. PubMed ID: 31823525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, and Pharmacokinetics of the Monoamine Oxidase B Inhibitor, HEC122505, and its Major Metabolite After Single- and Multiple- Ascending Dose, and Food Effect Study in Healthy Chinese Subjects.
    Jin C; Yi C; Chen K; Liang H
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):331-341. PubMed ID: 38446388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
    Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
    Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
    Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
    Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
    Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.
    Chandra KP; Shiwalkar A; Kotecha J; Thakkar P; Srivastava A; Chauthaiwale V; Sharma SK; Cross MR; Dutt C
    Clin Drug Investig; 2009; 29(9):559-75. PubMed ID: 19663519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
    Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
    CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A first in man study to evaluate the safety, pharmacokinetics and pharmacodynamics of RP7214, a dihydroorotate dehydrogenase inhibitor in healthy subjects.
    Nair A; Barde PJ; Routhu KV; Viswanadha S; Veeraraghavan S; Pak S; Peterson JA; Vakkalanka S
    Br J Clin Pharmacol; 2023 Mar; 89(3):1127-1138. PubMed ID: 36217901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
    J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
    Polasek TM; Leelasena I; Betscheider I; Marolt M; Kohlhof H; Vitt D; Fliegert F; Muehler AR
    Clin Pharmacol Drug Dev; 2023 May; 12(5):525-534. PubMed ID: 36938862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.